|Day Low/High||78.72 / 79.88|
|52 Wk Low/High||74.13 / 147.17|
Taking the measure of what's keeping the markets in the dumps.
Jim Cramer takes a closer look at Okta, Celgene, GasLog Partners, Neutral Tandem, Altria, Axovant Sciences, Lowe's and more.
Jim Cramer says investors need to be cautious, as trade tensions are just one of the things causing markets to whiplash. But he's got your game plan for next week.
Celgene Corporation (NASDAQ:CELG) today announced additional results from RELEVANCE, a phase III, randomized, open-label, international clinical study conducted in partnership with the Lymphoma Academic Research Organisation (LYSARC), were presented at...
Jim Cramer takes a closer look at General Electric, Celgene, Dollar Tree, STMicroelectronics, Chico's, Campbell Soup, Copart, Yext and more.
Jim Cramer says the market like this economy; he has your game plan for next week.
Celgene Corporation (NASDAQ:CELG) today announced results from the OPTIMISMM study, a phase III, randomized, open-label, international clinical study of the investigational combination regimen of POMALYST ® (pomalidomide), bortezomib and dexamethasone in...
Following up on a pledge to accelerate generic drugs into the marketplace to stoke price competition, the agency signals pending reform of the Risk Evaluation and Mitigation Strategy.
Celgene Corporation (NASDAQ:CELG) today announced the hiring of David V. Elkins as Executive Vice President (EVP), Chief Financial Officer (CFO).
ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG).
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
Stocks fall Thursday after Donald Trump calls off a summit meeting planned for next month with North Korea leader Kim Jong Un.
The Summit, N.J.-based biotech firm also plans to enter into an accelerated share repurchase program to buy back $2 billion of stock.
Celgene Corporation (NASDAQ: CELG) today announced that the Company's Board of Directors authorized the repurchase of an additional $3 billion of the Company's common stock.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Celgene Corporation (NASDAQ: CELG) today announced that data from more than 60 company-sponsored, cooperative group and investigator-initiated clinical studies evaluating Celgene agents will be presented at the American Society of Clinical Oncology Annual...
Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences and events where Celgene management will provide an overview of the Company.
After analyzing the biotech space, TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't have a catalyst for Celgene or Gilead.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks from the floor of the New York Stock Exchange.
Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.
Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Celgene Corporation (NASDAQ: CELG) who purchased shares between January 12, 2015 and February 27, 2018.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Celgene Corporation ("Celgene") (NASDAQ:CELG) securities...
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 29, 2018 to file lead plaintiff applications in a securities class action lawsuit against Celgene Corporation (NasdaqGS: CELG), if they purchased the Company's...
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.